Posted by Michael Wonder on 18 Oct 2020
First treatment for rare condition primary hyperoxaluria type 1
16 October 2020 - EMA has recommended granting a marketing authorisation in the European Union for Oxlumo (lumasiran) for the treatment of primary hyperoxaluria type 1.
Primary hyperoxaluria is a rare inherited disorder characterised by the overproduction of oxalate.
